ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0596

Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort

Diana Fernandez1, Rosana Quintana2, Karen Roberts3, Romina Nieto2, Marina Scolnik4, Carmen Funes Soaje5, CINTIA OTADUY6, Veronica Saurit7, Valeria Arturi8, GUILLERMO ARIEL BERBOTTO9, Maria Constanza Bertolaccini10, Mario Eduardo Kerzberg11, Maria de los Angeles Gargiulo12, Cecilia Pisoni13, Ana Carolina Ralle14, Joaquín Martinez Serventi15, Ana Silva16, ODIRLEI MONTICIELO17, Henrique Mariz18, Laíssa Cristina Alves Alvino19, Eduardo Borba20, Emily Figueiredo Neves Yuki21, Edgard Torres dos Reis-Neto22, Iris Guerra Herrera23, Milena Mimica24, Gustavo Aroca-Martínez25, Antonio Iglesias-Gamarra26, Carlos Alberto Cañas27, Gerardo Quintana-Lopez28, Carlos Toro-Gutierrez29, Mario Moreno Alvarez30, Olga-Lidia Vera-Lastra31, Margarita Portela Hernández32, Hilda Fragoso-Loyo33, Luis H Silveira34, Yelitza Gonzalez Bello35, Carlos Abud-Mendoza36, Jorge Antonio Esquivel Valerio37, Marcelo Barrios38, Lourdes Carolina Vázquez39, Magaly Alva Linares40, Manuel Ugarte-Gil41, Armando Calvo42, Roberto Muñoz-Louis43, Ana Carina Pizzarossa44, Gonzalo Silveira45, Federico Zazzetti46, Ashley Orillion47, Urbano Sbarigia48 and Guillermo Pons-Estel2, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 3Consultora externa de GLADEL, Rosario, Argentina, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 6Servicio de Reumatología Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 8Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, 10Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, 11Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 12Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires; Buenos Aires, Argentina, Buenos Aires, Argentina, 13CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 14Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 15Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, 16Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, 17Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 18Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 19Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, 20Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, 22Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, 23Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 24Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 25Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, 26Universidad Nacional de Colombia, Barranquilla, Colombia, 27Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 28Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 29Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 30Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 31División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, Mexico City, Mexico, 32Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 33Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 34Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 35Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, 36Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 37Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 38Hospital de Clínicas II, Uruguay, Uruguay, Uruguay, 39Facultad de Ciencias Médicas. Universidad Nacional de Asunción-Paraguay, Paraguay, Asunción, Paraguay, 40HOSPITAL EDGARDO REBAGLIATI MARTINS, San Borja, Peru, 41Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 42Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 43Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 44Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 45Facultad de Medicina - Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 46Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 47Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 48Johnson & Johnson, Beerse, Belgium

Meeting: ACR Convergence 2025

Keywords: American College of Rheumatology Criteria, Damage Index, gender, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the early stages of their disease.1,2 In the previous GLADEL cohort, male patients had a higher SLICC/ACR Damage Index (SDI) than their female counterparts, although this difference was not statistically significant.3 This study assessed organ damage, as measured by the SDI, as a function of gender in the GLADEL 2.0 cohort.

Methods: A total of 43 centers from 10 Latin American countries enrolled patients 18 years of age or older who met the 1982/1997 ACR and/or 2012 SLICC classification criteria. Descriptive analyses were conducted. An interaction analysis between gender and time was performed using a mixed-effects model in R. SDI was the dependent variable, while gender (between-subjects) and time (within-subjects) were the independent variables. A random intercept per participant was included to account for within-subject variability.Logistic regression modeling was used to examine the factors associated with changes in the SDI from baseline to the end of follow-up. A significance level of 5% was applied to all analyses and R version 4.4.0 software was used.

Results: Of the 1081 patients enrolled in the GLADEL 2.0 cohort, 385 patients matched by gender were considered. Of these, 190 completed at least four annual visits and were included in these analyses. Seventy percent of patients were women and 30% were men (Table 1). No statistically significant differences in organ damage, as measured by the SDI, were found between male and female patients (p=0.563). This trend remained consistent throughout the follow-up period, with no significant interactions observed (p=0.90). Damage accumulation over time increased significantly in both sexes (Figure 1A). The affected SDI domain frequency was examined both at baseline and during follow-up (Figure 1B). In general, males had a higher occurrence of ocular and cutaneous, and a moderate increase in malignant involvement compared to females, whereas females had a higher frequency of gastrointestinal, gonadal failure, pulmonary, peripheral vascular and musculoskeletal involvement. After adjusting for sociodemographic and clinical/immunologic characteristics, multivariate analysis revealed that disease duration (odds ratio [OR]: 1.05; 95% CI: 1.0-1.1) and disease activity, as measured by the SLEDAI-2K (OR: 1.05; 95% CI: 1.0-1.1), were associated with a higher likelihood of an increase in SDI.

Conclusion: Although male gender was not associated with an increased risk of damage accumulation, the proportion of patients with an increased SDI was higher in males than in females. Organ damage during follow-up increased significantly in both sexes. As patients in this cohort continue to be closely monitored, the impact of gender on damage accumulation may become more evident. References: Bruce IN, et al. Ann Rheum Dis. 2015;74:1706-13.Andrade RM, et al. Arthritis Rheum. 2007;56:622-30.García MA, et al. Lupus. 2005;14;938-046.

Supporting image 1Table 1. Sociodemographic and clinical characteristics of patients with SLE by gender

Supporting image 2Figure 1. (A) Mean SLICC/ACR score and (B) frequency of manifestations by SDI area by gender and follow-up time


Disclosures: D. Fernandez: None; R. Quintana: None; K. Roberts: None; R. Nieto: None; M. Scolnik: AstraZeneca, 2, 5, 6, GSK, 1, 5, 6, Janssen, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 1, 5, 6; C. Funes Soaje: None; C. OTADUY: None; V. Saurit: None; V. Arturi: None; G. BERBOTTO: None; M. Bertolaccini: None; M. Kerzberg: None; M. Gargiulo: None; C. Pisoni: None; A. Ralle: None; J. Serventi: None; A. Silva: AstraZeneca, 6, GSK, 6; O. MONTICIELO: None; H. Mariz: None; L. Alves Alvino: None; E. Borba: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (303378/2022-0), 5, GlaxoSmithKlein(GSK), 5; E. Figueiredo Neves Yuki: GlaxoSmithKlein(GSK), 5; E. Torres dos Reis-Neto: None; I. Guerra Herrera: None; M. Mimica: None; G. Aroca-Martínez: None; A. Iglesias-Gamarra: None; C. Cañas: None; G. Quintana-Lopez: None; C. Toro-Gutierrez: None; M. Moreno Alvarez: None; O. Vera-Lastra: None; M. Portela Hernández: None; H. Fragoso-Loyo: None; L. Silveira: None; Y. Gonzalez Bello: None; C. Abud-Mendoza: None; J. Esquivel Valerio: None; M. Barrios: None; L. Vázquez: None; M. Alva Linares: None; M. Ugarte-Gil: AstraZeneca, 2, 6, Ferrer, 2, 6, GSK, 2, 6, Johnson & Johnson, 5, Novartis, 2, 6, Tecnofarma, 2, 6; A. Calvo: None; R. Muñoz-Louis: None; A. Pizzarossa: None; G. Silveira: None; F. Zazzetti: Johnson & Johnson, 3, 11; A. Orillion: Johnson & Johnson, 3, 11; U. Sbarigia: Johnson and Johnson, 11; G. Pons-Estel: AstraZeneca, 1, 6, GlaxoSmithKlein(GSK), 1, 6, Janssen, 1, 6.

To cite this abstract in AMA style:

Fernandez D, Quintana R, Roberts K, Nieto R, Scolnik M, Funes Soaje C, OTADUY C, Saurit V, Arturi V, BERBOTTO G, Bertolaccini M, Kerzberg M, Gargiulo M, Pisoni C, Ralle A, Serventi J, Silva A, MONTICIELO O, Mariz H, Alves Alvino L, Borba E, Figueiredo Neves Yuki E, Torres dos Reis-Neto E, Guerra Herrera I, Mimica M, Aroca-Martínez G, Iglesias-Gamarra A, Cañas C, Quintana-Lopez G, Toro-Gutierrez C, Moreno Alvarez M, Vera-Lastra O, Portela Hernández M, Fragoso-Loyo H, Silveira L, Gonzalez Bello Y, Abud-Mendoza C, Esquivel Valerio J, Barrios M, Vázquez L, Alva Linares M, Ugarte-Gil M, Calvo A, Muñoz-Louis R, Pizzarossa A, Silveira G, Zazzetti F, Orillion A, Sbarigia U, Pons-Estel G. Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/effect-of-gender-and-follow-up-time-in-damage-accrual-data-from-a-latin-america-lupus-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-gender-and-follow-up-time-in-damage-accrual-data-from-a-latin-america-lupus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology